scholarly journals Clinical and Translational Challenges in Gene Therapy of Cardiovascular Diseases

10.5772/54075 ◽  
2013 ◽  
Author(s):  
Divya Pankajakshan ◽  
Devendra K.
Keyword(s):  
Gene Therapy ◽  
Cardiovascular Diseases

Gene Therapy in Cardiovascular Diseases

2002 ◽  
Vol 2 (4) ◽  
pp. 427-435 ◽  
Author(s):  
Kamala Tamirisa ◽  
Debabrata Mukherjee
Keyword(s):  
Gene Therapy ◽  
Cardiovascular Diseases

Gene therapy in cardiovascular diseases: A review of recent updates

2018 ◽  
Vol 119 (12) ◽  
pp. 9645-9654 ◽  
Author(s):  
Armita M. Gorabi ◽  
Saeideh Hajighasemi ◽  
Hossein A. Tafti ◽  
Masoud Soleimani ◽  
Yunes Panahi ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Cardiovascular Diseases

Unlockable Nanocomplexes with Self-Accelerating Nucleic Acid Release for Effective Staged Gene Therapy of Cardiovascular Diseases

2018 ◽  
Vol 30 (31) ◽  
pp. 1801570 ◽  
Author(s):  
Jing-Jun Nie ◽  
Bokang Qiao ◽  
Shun Duan ◽  
Chen Xu ◽  
Boya Chen ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Nucleic Acid ◽  
Cardiovascular Diseases ◽  
Acid Release

The Emerging Role of Gene Therapy in the Treatment of Cardiovascular Diseases

2003 ◽  
Vol 40 (5) ◽  
pp. 499-545 ◽  
Author(s):  
Joel E. Barbato ◽  
Melina R. Kibbe ◽  
Edith Tzeng
Keyword(s):  
Gene Therapy ◽  
Cardiovascular Diseases

Nanomedicine has elegantly attempted to cure multiple gene polymorphisms and mutations in cardiovascular diseases using gene therapy techniques.

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Gene Therapy ◽  
Heart Disease ◽  
Cardiovascular Diseases ◽  
Gene Polymorphisms ◽  
Distribution Systems ◽  
Genetic Factors ◽  
Multiple Gene ◽  
Complex Interactions ◽  
Direct Delivery ◽  
Vector Delivery

The molecular mediators that induce MI, the loss of myocardial regeneration, and the development of heart disease are all being researched more thoroughly. It's intriguing to think about how genetic factors could be used to modulate these disease mediators. DNA, RNA, or proteins may both be included in this operation. However, direct delivery of these biomolecules is not always effective. Using gene therapy methods, nanomedicine has elegantly attempted to reverse many gene polymorphisms and defects in complex diseases.The stability of these biomolecules, as well as their controlled release and passage through barriers to the operating site, can be aided by delivery systems. Precision-tailored vector delivery has been shown to reduce toxicity and improve drug availability. Currently, a variety of distribution systems are being evaluated, with the frontrunners incorporating security and conclusions being selected.New biological mediators, as well as the complex interactions within them, as well as their pharmacokinetic and pharmacodynamic profiles, will be discovered in the future. This opens the door to a more advanced delivery system that meets the biological requirements for maximum therapeutic efficacy.

Gene Therapy for Cardiovascular Diseases

2016 ◽  
pp. 377-387
Author(s):  
Thomas Weber ◽  
Lior Zangi ◽  
Roger J. Hajjar
Keyword(s):  
Gene Therapy ◽  
Cardiovascular Diseases
Sign in / Sign up

Export Citation Format

Share Document